News

Quick Hits: Cannabis news in brief

Published on August 22, 2025 by Pat Bulmer

Photo: Adobe Stock/the oz.

Cannabis news in brief: Cannara’s real estate deal; Recall over label mistake; Vaping unpopular in BC; Vancouver airport bust; Tilray wants NASDAQ leeway; Medical cannabis good for Aurora 

Sale boosts Cannara’s bank account

Quebec’s Cannara Biotech has made a $5.5-million sale.

The cannabis company announced it has sold a “non-core building under construction and a related parcel of land located at its Valleyfield site for total proceeds of $5.5 million.”

“As a result of the transaction, the net proceeds of $5.45 million will be applied toward reducing the principal balance of Cannara’s existing term loan, effectively decreasing the company’s long-term debt,” the company said in a news release.

“Reducing our debt by $5.45 million further enhances Cannara’s capital structure and supports future margin expansion,” said CFO Nicholas Sosiak.

Pre-rolls recalled for labelling error

A Quebec company’s pre-rolls have been recalled.

Health Canada says Terranueva Pharma’s Nueva+ Le Fameux dried cannabis pre-rolls were recalled because of incorrect labelling.

“The product label has incorrect cannabinoid values, where the total THC labelled is lower than the actual total THC in the product,” Health Canada says on its website.

“To date, Terranueva Pharma Corporation and Health Canada have not received any complaints related to the recalled lot. Neither Terranueva Pharma Corporation nor Health Canada have received any adverse reaction reports for the recalled cannabis product lot,” Health Canada said.

A total of 1,248 units were sold in Quebec from July 22 to Aug. 11.

Consumers can return the product to their retailer, if they want. Look for lot number 202503LF.

Vaping not welcome in multi-family buildings

Three-quarters of British Columbians think smoking and vaping (tobacco and cannabis) should be banned in multi-family buildings.

Currently, there is no provincewide regulation that addresses smoking or vaping in multi-family buildings.

A poll conducted by Research Co. found 77% of British Columbians favour a smoking ban and 73% a vaping ban in multi-family buildings.

Otherwise, the poll found strong support (over 80%) for existing bans in most public places — with one exception. A few more respondents — about one-third — tolerate smoking and vaping at parks and beaches.

Across the province, 23% of British Columbians said they smoked marijuana in the past year, while 19% smoked tobacco or consumed marijuana in a non-smoking form.

Half of British Columbians (50%) say they would not consider dating a person who smoked marijuana.

More British Columbians said they would not consider dating a person who vaped (57%) or who smoked tobacco (62%).

Results are based on an online survey conducted July 13-15 among 814 adults. The data has been statistically weighted for age, gender and region. The margin of error is +/- 3.1 percentage points, 19 times out of 20. Research Co. is led by pollster Mario Canseco.

Quick Hits

🔐 Safe and sound: Cannabis stores calling on province for better security in Manitoba (CityNews)

🛒 Another one: Abbotsford council approves new cannabis retail store (Abby News)

🇺🇸 Classified? Trump reportedly considers reclassifying marijuana as less dangerous drug (The Guardian)

🌲 Weed war: First Nation at centre of Oka Crisis gripped by environmental battles linked to cannabis megastores (CBC)

🏷️ Labelled: B.C.’s cannabis industry wants changes to how products are labelled (CTV)

💰 Targeted: Unexplained wealth order issued in BC against alleged pot growers (Vancouver Sun)

29 kg of cannabis found in suitcases

Canada Border Services Agency officers at Vancouver airport seized 29 kilograms of cannabis from the suitcases of a traveller headed to Amsterdam.

The traveller was arrested and turned over to the RCMP, the CBSA said in a social media post on Aug. 8.

Tilray needs more time

Tilray, the Canadian-American cannabis and liquor giant, is asking for more time to comply with the Nasdaq stock exchange’s listing requirements.

Among other rules, Nasdaq requires stock to be valued at a minimum of $1 for at least 10 days.

Tilray’s stock was $1.43 Cdn on the TSX on Aug. 15.

Tilray is looking at measures it can take to boost its stock price.

“Tilray’s trading levels have appreciated in recent weeks following President Trump’s review of cannabis rescheduling,” said CEO Irwin Simon in a news release.

The Trump administration has said it is considering reclassifying cannabis from a Schedule 1 drug — along with heroin, LSD, ecstasy and others — to Schedule 3, where medicinal uses may be allowed.

After the announcement, Tilray stock jumped nearly 42%, while Canada’s Village Farms and Canopy Growth closed up about 34% and 26%, respectively, al Jazeera reported.

“Tilray has multiple options to meet Nasdaq’s requirements, and with this extension request, we are giving the market additional time to demonstrate its confidence in our long-term strategy,” Simon said.

Medical cannabis still strong for Aurora

Not much changed in a month for Edmonton-based Aurora Cannabis. The company issued an annual financial report a month ago that highlighted the strength of its medical cannabis business.

And now, a quarterly report for the period ending June 30 reports much the same.

“Global medical cannabis net revenue rose 37%, supported by 85% growth in international markets, most notably Germany and Poland, alongside growth in Canadian medical cannabis and record contributions from our plant propagation business.” said CEO Miguel Martin.

Total net revenue for the quarter was $98 million, compared to $83.4 million in the same time period a year ago.

The 17% increase was credited to growth in global medical sales business and a 4% increase in plant propagation (Bevo Farms), offset by a 32% decrease in consumer cannabis revenue, which the company has deliberately downplayed to focus on the medical side.

For the next quarter, Aurora says it anticipates continued growth in the medical cannabis business.

Aurora also announced it is launching two flower products in Australia from its Whistler Cannabis craft operation — Ginger Breath, a 32%-THC indica strain; and Critical Diesel, 28% THC, sativa.